Baku, Azerbaijan, Jan. 30
By Elmira Tariverdiyeva - Trend:
Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announced that its first
successful adipose derived stem cell (ADSC) implantation was performed in Azerbaijan at Baku Central Military Hospital, according to The Wall Street Journal.
"Stem cell therapy is literally changing medicine today as we know it. Bioheart is thrilled to bring these treatments to patients all over the world who are currently suffering from debilitating diseases but who have limited treatment options," said Kristin Comella, Bioheart's Chief Scientific Officer.